22-Apr-2024
Goldman’s debt issuers stocks basket
Seeking Alpha News (Mon, 22-Apr 12:53 PM ET)
Dividend yield and growth stock list by Goldman
Seeking Alpha News (Mon, 22-Apr 11:04 AM ET)
Piper Sandler Sticks to Its Buy Rating for Amgen (AMGN)
TipRanks (Mon, 22-Apr 8:27 AM ET)
13 new obesity drugs could hit the market by 2029 amid surging demand
Seeking Alpha News (Sun, 21-Apr 8:04 PM ET)
Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons
TipRanks (Thu, 18-Apr 12:29 AM ET)
AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024
PRNewswire (Tue, 16-Apr 5:26 PM ET)
AMGEN PRESENTS NEW RESEARCH ON OTEZLA (APREMILAST) AT AAD 2024
PRNewswire (Sat, 9-Mar 12:20 PM ET)
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
PRNewswire (Wed, 6-Mar 4:00 PM ET)
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
PRNewswire (Thu, 29-Feb 4:00 PM ET)
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
PRNewswire (Mon, 26-Feb 9:00 AM ET)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen trades on the NASDAQ stock market under the symbol AMGN.
As of April 22, 2024, AMGN stock price climbed to $271.91 with 1,816,918 million shares trading.
AMGN has a beta of 0.28, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.02 to the broad based SPY ETF.
AMGN has a market cap of $145.72 billion. This is considered a Large Cap stock.
Last quarter Amgen reported $8 billion in Revenue and $4.71 earnings per share. This beat revenue expectation by $66 million and exceeded earnings estimates by $.09.
In the last 3 years, AMGN stock traded as high as $329.72 and as low as $198.64.
The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, VOO, QQQ, SCHD, SPY.
AMGN has underperformed the market in the last year with a return of +15.0%, while the SPY ETF gained +22.9%. In the last 3 month period, AMGN fell short of the market, returning -11.6%, while SPY returned +3.7%. However, in the most recent 2 weeks AMGN has outperformed the stock market by returning +1.0%, while SPY returned -3.7%.
AMGN support price is $264.95 and resistance is $272.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN stock will trade within this expected range on the day.